灯盏细辛联合倍他司汀对椎-基底动脉供血不足的疗效及血管内皮功能指标变化  

The Therapeutic Effect of Vertebral-basilar Artery Insufficiency by Treating with Erigeron Breviscapus and Betahistine and Its Impact on the Indexes of Vascular Endothelial Function

作　　者：易蕾[1] 雷蕾[2] 杜丹心 张明洁[3] 

机构地区：[1]武汉科技大学附属天佑医院药品采购与调剂科,武汉430064 [2]武汉科技大学附属天佑医院神经内科,武汉430064 [3]武汉科技大学附属天佑医院检验科,武汉430064

出　　处：《微循环学杂志》2015年第3期34-37,共4页Chinese Journal of Microcirculation

摘　　要：目的:回顾性分析灯盏细辛+倍他司汀治疗椎-基底动脉供血不足(VBI)的临床疗效及对患者血管内皮功能指标血浆内皮素-1(ET-1)、血管性血友病因子(vWF)和血清一氧化氮(NO)水平的影响。方法:140例临床确诊VBI患者,按随机数字表法分为治疗对照组(n=70,采用倍他司汀片治疗)和联合治疗组(n=70,采用灯盏细辛注射液+倍他司汀片治疗)。治疗14天后,观察比较两组临床疗效以及ET-1、vWF和NO水平变化和组间差异。结果:联合治疗组显效率及总有效率分别为71.42%和91.43%,明显优于治疗对照组的45.71%和78.57%(P<0.05);治疗前,与正常对照组比较,两组VBI患者ET-1及vWF水平均明显升高,NO水平显著下降(P<0.05);治疗后,联合治疗组ET-1及vWF水平较治疗前及治疗对照组治疗后均明显降低(P<0.01),NO水平均明显升高(P<0.01),且恢复至正常对照组水平(P>0.05)。两组治疗期间均未发生脑及其它脏器出血等药物不良反应。结论:灯盏细辛+倍他司汀能显著改善VBI患者血管内皮功能,提高临床疗效。Objective： To analysis of the therapeutic effect to vertebral-basilar artery insufficiency （VBI） patients by treating with erigeron breviscapus and betahistine, and then observe its impact on the levels of endothelin- 1 （ET-1）, yon wiilebrand factor （vWF） and nitrogen monoxide （NO）. Method： 140 cases of clinically diagnosed patients with VBI were divided into control treatment group （n=70, only treated with betahistine） and combined treatment group （n=70, treated with a combination therapy of erigeron breviscapus and betahistine） according to the random number table. The therapeutic effect after 14 - days＇ treatment and the levels of ET-1, vWF and NO of the 140 patients were detected. Results： After treatment, the significant efficiency and total effective efficiency of the combined treatment group were 71.42% and 91.43% respectively, which were apparently superior to 45.71% and 78.57% of the control treatment group （P〈0.05）. Before the treatment, compared with the normal control group, patients with VBI had increased levels of ET-1 and vWF and decreased level of NO （P〈0.05）. Then after treatment, the levels of ET-1 and vWF of the combined treatment group decreased significantly compared with that before treatment and with that of the control treatment group （P〈0.01）. The level of NO increased significantly after the combination treatment （P〈0.01）, and it almost returned back to normal control levels （P〉0.05）. There was not any bleeding in patients＇ brains or other organs during the treatments. Conclusion： Erigeron breviscapus combined with betahistine treatment can make significant improvements in VBI patients＇ vascular endothelial function and enhance the therapeutic effect.

关 键 词：椎-基底动脉供血不足 灯盏细辛 倍他司汀 内皮素-1 血管性血友病因子 一氧化氮 

分 类 号：R743[医药卫生—神经病学与精神病学]